We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dysfunction (ED) and Dyslipidemia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00379756
First Posted: September 22, 2006
Last Update Posted: August 16, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
GlaxoSmithKline
  Purpose
This is a study consisting of four periods (screening, run-in, treatment, follow-up). A four-week treatment-free, run-in period where the subject will make at least four attempts at intercourse on four separate days with at least 50% of the attempts must be unsuccessful. During run-in the subjects will be using a stopwatch to measure the time from erection perceived hard enough for penetration until withdrawal from the partner's vagina. Next there are 12 weeks of treatment with either placebo or LEVITRA. Each subject will be required to visit the clinic on 5 occasions over a period of 4 months.

Condition Intervention Phase
Erectile Dysfunction Drug: LEVITRA (vardenafil) Drug: placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Erectile function (EF) domain score of the International Index of Erectile Function (IIEF) [ Time Frame: Up to Week 12 ]
    The IIEF questionnaire is a validated 15-item instrument that assesses the participant's erectile function over the previous 4 weeks. The IIEF includes 5 domains affecting male sexual function: erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction. Responses to the IIEF were re-coded using a standard coding method, where more positive responses received a higher score. The EF domain score was calculated as the sum of the re-coded scores from questions 1-5 and 15, using last observation carried forward (LOCF). Scores range from 1 (lowest) to 30 (highest). If two or more items in the EF domain were missing, the EF domain score was considered to be missing.

  • Mean success rate of insertion based on attempts [ Time Frame: Up to Week 12 ]
    Success rate of insertion was derived from the Sexual Encounter Profile (SEP) Question 2 (SEP-2) of the participant's diary that asked 'Were you able to insert your penis into your partner's vagina?'. Responses were either Yes or No. Patients were instructed to complete diary questions as soon as possible after each sexual attempt, but no later than 24 hours after the attempt. The per-participant overall success rate for insertion was calculated by dividing the number of successful attempts (SEP-2=yes) over 12 weeks by the total number of valid attempts recorded over 12 weeks. If the participant was not able to make any valid attempts in 12 weeks, the participant was non-evaluable. Per-participant success rates were then averaged at the group level to obtain the mean success rate from Weeks 0-12.

  • Mean success rates of maintenance based on attempts [ Time Frame: Up to Week 12 ]
    Success rate of maintenance was derived from the SEP Question 3 (SEP-3) of the participant's diary that asked 'Did your erection last long enough for you to have successful intercourse?'. Responses were either Yes or No. Participants were instructed to complete diary questions as soon as possible after each sexual attempt, but no later than 24 hours after the attempt. The per-participant overall success rate for maintenance was calculated by dividing the number of successful attempts (SEP-3=yes) over 12 weeks by the total number of valid attempts recorded over 12 weeks. If the participant was not able to make any valid attempts in 12 weeks, the participant was non-evaluable. Per-participant success rates were then averaged at the group level to obtain the mean success rate from Weeks 0-12.


Secondary Outcome Measures:
  • Mean duration of erection leading to completion of successful intercourse as measured by Sexual Encounter Profile Question 3 [SEP-3] [ Time Frame: Up to Week 12 ]
    Duration of erection leading to completion of successful intercourse was derived from data recorded in the participant's diary. For each diary entry, the time from erection perceived hard enough for penetration until withdrawal from partner's vagina was measured by stopwatch and recorded in the participant's diary. For diary entries where SEP-3=yes, this recorded duration was used in calculations of a per-participant median duration. For diary entries where SEP-3=no, a duration of 0 was used to calculate the per-participant median. The per-participant median values averaged at the group level to obtain the mean duration of erection leading to completion of successful intercourse as measured by SEP-3.

  • Change from Baseline in scores for questions on the IIEF questionnaire and scores of the other non-EF domains of the IIEF [ Time Frame: Up to Week 12 ]
    Non-EF domains of the IIEF (Intercourse Satisfaction, Orgasmic Function, Sexual Desire, Overall Satisfaction) and IIEF questions (Erection during sexual activity?, Hard enough for penetration?, Able to penetrate partner?, Maintain your erection?, Maintain to completion?, Times attempted intercourse, Satisfactory for you?, Enjoyed sexual intercourse?, How often did you ejaculate?, How often feeling of orgasm?, How often felt sexual desire?, Rate level of sexual desire?, How satisfied with sex life?, Satisfied with sexual relationship? and Confidence to get, keep erection?) scores were assessed at Week 4, Week 8 and Week 12. The Baseline was the value at Week 0. Change from Baseline was the post-Baseline value minus Baseline value.

  • Number of participants with normal erectile function having EF domain scores of 26 and above [ Time Frame: Up to Week 12 ]
    The EF domain score was calculated by summing recoded responses to Questions 1-5 and 15, for each participant. It ranged from 1 to 30. EF domain scores were dichotomized as either normal (26 and above) or below normal (below 26) using LOCF, to calculate number of participants returning to normal erectile function. For the EF domain score the total was considered to be missing if 2 or more answers in the domain were missing.

  • Change from Baseline in participant's diary results [ Time Frame: Up to Week 12 ]
    Electronic diaries were provided to participants. Participants were supposed to complete the diary questions as soon as possible after each sexual attempt but no later than 24 hours after the attempts. The diary questions (Ability to achieve at least some erection, Ability to insert penis into partner's vagina, Long enough erection having successful intercourse, Satisfied with the hardness of erection, Satisfied with this sexual experience, Ability to ejaculate) response rates were presented for Weeks 0-12. The Baseline was the value at Week 0. Change from Baseline was the post-Baseline value minus Baseline value.

  • Mean duration of erection regardless of SEP-3 Response [ Time Frame: Up to Week 12 ]
    Duration of erection was time from erection perceived hard enough for penetration (start stopwatch) until withdrawal from the partner's vagina (stop stopwatch) regardless of completion of successful intercourse. The data was presented for overall period from Week 0 to Week 12.

  • Change from Baseline in duration of erection leading to completion of successful intercourse. [ Time Frame: Up to Week 12 ]
    Duration of erection was time from erection perceived hard enough for penetration (start stopwatch) until withdrawal from the partner's vagina (stop stopwatch) leading to completion of successful intercourse. The data was presented for overall period from Week 0 to Week 12. The Baseline was the value at Week 0. Change from Baseline was the post-Baseline value minus Baseline value.

  • Number of participants with response 'Yes' for Global Assessment Question [ Time Frame: Up to Week 12 ]
    The participants were asked to complete the self-administered Global Assessment Question. The question asked was 'has the treatment you have been taking over the past 4 weeks improved your erections'. The response was either Yes or No depending on comparison to participant's erections before their participation in this study. For the scale missing values remained missing.

  • Mean score for Keep It Simple (KIS) scale [ Time Frame: Up to Week 12 ]
    The KIS scale was a self-reported visual analog scale (VAS) from 0 to 10 designed to assess erections as 'how do you grade your erections over the last 4 weeks?'. For the scale missing values remained as missing.


Enrollment: 395
Actual Study Start Date: May 22, 2006
Study Completion Date: May 17, 2007
Primary Completion Date: May 17, 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Levitra
10mg x 4 weeks, with option to increase to 20mg aat that time if desired
Drug: LEVITRA (vardenafil)
active comparator
Placebo Comparator: placebo Drug: placebo
placebo comparator

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Males with ED for more than six months, according to the NIH Consensus Statement (inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance).
  • Stable heterosexual relationship for more than 6 months.
  • The subject must make at least four attempts at sexual intercourse (according to the question in the subject diary: Was sexual activity initiated with the intention of intercourse?) on four separate days during the untreated baseline period. At least 50% of attempts during this period must be unsuccessful, according to the following questions from the subject diary [at least one question should be answered "No"]: Were you able to achieve at least some erection (some enlargement of the penis)? Were you able to insert your penis into your partner's vagina? Did your erection last long enough for you to have successful intercourse?
  • Diagnosis of dyslipidemia treated with a stable dose of a statin for 6 months at Visit 1.
  • IIEF-EF domain score of 25 denoting mild to severe ED at Visit 2.
  • Documented, dated, written Informed Consent.

Exclusion criteria:

  • Premature ejaculator <2 minutes
  • Any unstable medical, psychiatric, spinal cord injury, penile anatomical abnormalities, or substance abuse disorder that MD feels subject will not be able to complete the study.
  • Low sexual desire.
  • Prior prostatectomy surgery
  • Severe chronic or acute liver disease, history of moderate or severe liver impairment
  • Clinically significant chronic hematological disease
  • Bleeding disorder or significant active peptic ulceration.
  • Cardiovascular conditions that prevent sexual activity.
  • History of heart attack, stroke, or life-threatening arrhythmia within the prior 6 months.
  • hypotension or hypertension at rest.
  • cancer within the past 5 years. Use of these medications: nitrates or nitric oxide donors, anti-androgens, oral or injectable androgens, received any investigational drug (including placebo) within 30 days of screening (Visit 1).
  • Use of any treatment for ED within 7 days of screening including oral medications, vacuum devices, constrictive devices, injections or urethral suppositories.
  • Subjects who are taking the following potent inhibitors of cytochrome P-450 3A4.
  • Abnormal Laboratory Values:

    1. serum total testosterone level >25% below the lower limit of normal
    2. serum creatinine >3.0 mg/dl.
    3. AST and/or ALT >3x the upper limit of normal.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00379756


  Hide Study Locations
Locations
United States, Alabama
GSK Investigational Site
Fairhope, Alabama, United States, 36532
GSK Investigational Site
Homewood, Alabama, United States, 35209
GSK Investigational Site
Huntsville, Alabama, United States, 35801
United States, Arizona
GSK Investigational Site
Phoenix, Arizona, United States, 85016
GSK Investigational Site
Phoenix, Arizona, United States, 85023
United States, California
GSK Investigational Site
Concord, California, United States, 94520
GSK Investigational Site
Huntington Park, California, United States, 90255
GSK Investigational Site
Long Beach, California, United States, 90806
GSK Investigational Site
Modesto, California, United States, 95350
GSK Investigational Site
Newport Beach, California, United States, 92660
GSK Investigational Site
Orangevale, California, United States, 95662
GSK Investigational Site
Santa Ana, California, United States, 92705
GSK Investigational Site
Walnut Creek, California, United States, 94598
United States, Colorado
GSK Investigational Site
Denver, Colorado, United States, 80210
GSK Investigational Site
Wheat Ridge, Colorado, United States, 80033
United States, Connecticut
GSK Investigational Site
New Britain, Connecticut, United States, 06052
United States, Florida
GSK Investigational Site
Aventura, Florida, United States, 33180
GSK Investigational Site
Clearwater, Florida, United States, 33761
GSK Investigational Site
Coral Gables, Florida, United States, 33134
GSK Investigational Site
Fort Myers, Florida, United States, 33916
GSK Investigational Site
North Miami, Florida, United States, 33161
GSK Investigational Site
Orlando, Florida, United States, 32803
GSK Investigational Site
Pembroke Pines, Florida, United States, 33024
GSK Investigational Site
Pinecrest, Florida, United States, 33156
GSK Investigational Site
Saint Petersburg, Florida, United States, 33710
GSK Investigational Site
Sarasota, Florida, United States, 34237
GSK Investigational Site
South Miami, Florida, United States, 33143
GSK Investigational Site
Tampa, Florida, United States, 33607
GSK Investigational Site
West Palm Beach, Florida, United States, 33401
United States, Georgia
GSK Investigational Site
Atlanta, Georgia, United States, 30342
GSK Investigational Site
Columbus, Georgia, United States, 31904
GSK Investigational Site
Dawsonville, Georgia, United States, 30534
GSK Investigational Site
Roswell, Georgia, United States, 30076
GSK Investigational Site
Woodstock, Georgia, United States, 30189
United States, Indiana
GSK Investigational Site
Avon, Indiana, United States, 46123
GSK Investigational Site
Evansville, Indiana, United States, 47714
GSK Investigational Site
Fort Wayne, Indiana, United States, 46825
GSK Investigational Site
Jeffersonville, Indiana, United States, 47130
United States, Kansas
GSK Investigational Site
Wichita, Kansas, United States, 67207
United States, Kentucky
GSK Investigational Site
Lexington, Kentucky, United States, 40509
GSK Investigational Site
Madisonville, Kentucky, United States, 42431
United States, Louisiana
GSK Investigational Site
Shreveport, Louisiana, United States, 71106
United States, Maine
GSK Investigational Site
Swansea, Maine, United States, 02777
United States, Massachusetts
GSK Investigational Site
Taunton, Massachusetts, United States, 02780
United States, Michigan
GSK Investigational Site
Kalamazoo, Michigan, United States, 49009
United States, Minnesota
GSK Investigational Site
Saint Louis Park, Minnesota, United States, 55416
United States, Missouri
GSK Investigational Site
Saint Louis, Missouri, United States, 63117
United States, Nebraska
GSK Investigational Site
Omaha, Nebraska, United States, 68134
United States, Nevada
GSK Investigational Site
Las Vegas, Nevada, United States, 89119
United States, New Jersey
GSK Investigational Site
Lawrenceville, New Jersey, United States, 08648
United States, New York
GSK Investigational Site
New York, New York, United States, 10016
GSK Investigational Site
Rochester, New York, United States, 14609
GSK Investigational Site
West Seneca, New York, United States, 14224
United States, North Carolina
GSK Investigational Site
Charlotte, North Carolina, United States, 28262
GSK Investigational Site
Fayetteville, North Carolina, United States, 28304
GSK Investigational Site
Winston-Salem, North Carolina, United States, 27103
United States, Pennsylvania
GSK Investigational Site
Shippensburg, Pennsylvania, United States, 17257
United States, Tennessee
GSK Investigational Site
Nashville, Tennessee, United States, 37203
United States, Texas
GSK Investigational Site
Amarillo, Texas, United States, 79106
United States, Utah
GSK Investigational Site
Salt Lake City, Utah, United States, 84107
United States, Virginia
GSK Investigational Site
Norfolk, Virginia, United States, 23502
GSK Investigational Site
Richmond, Virginia, United States, 23294
United States, Washington
GSK Investigational Site
Seattle, Washington, United States, 98166
United States, Wisconsin
GSK Investigational Site
Menomonee Falls, Wisconsin, United States, 53051
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53209
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00379756     History of Changes
Other Study ID Numbers: 106718
First Submitted: September 21, 2006
First Posted: September 22, 2006
Last Update Posted: August 16, 2017
Last Verified: August 2017

Keywords provided by GlaxoSmithKline:
Erectile dysfunction, impotence

Additional relevant MeSH terms:
Dyslipidemias
Erectile Dysfunction
Lipid Metabolism Disorders
Metabolic Diseases
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders
Vardenafil Dihydrochloride
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents